Curcumin’s effect in advanced and metastatic breast cancer patients treated with first or second-line docetaxel: A randomized trial (2024)

Peer-Reviewed Study · Judith PJ, Maureen B, Melanie P, Fabrice K, et al. (Centre Jean Perrin group) · September 16, 2024

Judith PJ et al., 2024-09-16: Randomised phase II trial in 42 patients with advanced breast cancer: adding oral curcumin to docetaxel did not improve objective response (55.6% vs 73.7% with docetaxel alone, p = 0.25).

no difference was observed for the objective response rate (p = 0.25, control 73.7% vs. experimental 55.6%).

Abstract, Results

Judith PJ et al., 2024-09-16: Randomised phase II trial in 42 patients with advanced breast cancer: adding oral curcumin to docetaxel did not improve objective response (55.6% vs 73.7% with docetaxel alone, p = 0.25). Open-label, interim analysis on 37 patients. Numerical disadvantage in the curcumin arm is not statistically significant and should not be read as harm. Comparator: docetaxel alone. Study type: randomized trial.